Biomarin Pharmaceutical (BMRN) Finished Goods (2010 - 2021)

Biomarin Pharmaceutical has disclosed Finished Goods across 12 years of filings, most recently posting $261.6 million for Q3 2021.

• Quarterly Finished Goods fell 20.79% year-over-year to $261.6 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $261.6 million (down 20.79% YoY) and the FY2020 annual result came in at $313.6 million, up 22.57% from the prior year.
• Finished Goods climbed to $261.6 million in Q3 2021, from $253.3 million in the prior quarter.
• Over five years, Finished Goods peaked at $330.3 million in Q3 2020 and troughed at $129.6 million in Q2 2017.
• A 5-year average of $226.5 million and a median of $220.9 million in 2018 frame the typical range for Finished Goods.
• Annual changes were most pronounced in 2018 — Finished Goods soared 70.09% — and 2021, when it retreated 20.79%.
• Tracing BMRN's Finished Goods over 5 years: stood at $191.2 million in 2017, then gained by 17.76% to $225.2 million in 2018, then grew by 13.62% to $255.9 million in 2019, then climbed by 22.57% to $313.6 million in 2020, then decreased by 16.56% to $261.6 million in 2021.
• Business Quant data shows BMRN's Finished Goods at $261.6 million in Q3 2021, $253.3 million in Q2 2021, and $279.6 million in Q1 2021.